Investors need to pay close attention to AngioDynamics (ANGO) stock based on the movements in the options market lately.
This company is a small player in the steadily growing medtech industry.
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in second-quarter fiscal 2023.
AngioDynamics (ANGO) delivered earnings and revenue surprises of 200% and 1.65%, respectively, for the quarter ended November 2022. Do the numbers hold clues to what lies ahead for the stock?
AngioDynamics: Fiscal Q2 Earnings Snapshot
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and...
SARTORIUS (SARTF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road....
As COVID-19 headwinds fade, AngioDynamics' business could rebound.
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and...